Latest news

• Roche and NHS England hail pricing deal on MS drug Ocrevus

  Another pricing deal on high cost medicine. NHS England is claiming another successful negotiation with pharma after it agreed a lower price with Roche for its multiple sclerosis treatment Ocrevus. ... NICE last year recommended Ocrevus for some adults

• Hemlibra off to a flyer as Roche raises 2019 forecasts

  However, new drugs including Ocrevus (ocrelizumab) for multiple sclerosis, cancer immunotherapy Tecentriq (atezolizumab) and new haemophilia drug Hemlibra (emicizumab) acted as a buffer. ... Ocrevus sales came in at CHF 836m in the quarter, up two thirds

• FDA approves Novartis' next-gen MS drug Mayzent

  Analysts predict Mayzent will hit peak sales of up to $3bn, but will have to battle hard with competitors such as Roche's MS star drug Ocrevus.  It is used in ... Mayzent will be priced slightly higher than Ocrevus at $88, 000 per year, but according to

• Ocrevus helps Roche shrug off biosimilars in 2018

  Multiple sclerosis therapy Ocrevus (ocrelizumab, pictured above) was once again the star of the show, rising 172% to 2.35bn francs in its first full calendar year on the market, making

• Novartis: pipeline will generate 60 filings in three years

  Following after in MS is ofatumumab, a potential rival to Roche’s fast-growing CD20-targeting drug Ocrevus (ocrelizumab) that is already approved to treat blood cancers under the Arzerra (brand